RPT-Profit on $475,000 Novartis cancer drug could be a while coming

ZURICH, Aug 31 (Reuters) – Novartis’s newgene-modifying cancer therapy’s $475,000-per-patient stickerprice has drawn fire from advocate groups calling for cheaperdrugs, but analysts said the Swiss drugmaker could initiallystruggle to break even.
The post RPT-Profit on $475,000 Novartis cancer drug could be a while coming appeared first on RocketNews | Top News Stories From Around the Globe.